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ABSTRACT
Deregulation of multiple DNA repair pathways may contribute to aggressive 
biology and therapy resistance in gliomas. We evaluated transcript levels of 157 genes 
involved in DNA repair in an adult glioblastoma Test set (n=191) and validated in ‘The 
Cancer Genome Atlas’ (TCGA) cohort (n=508). A DNA repair prognostic index model 
was generated. Artificial neural network analysis (ANN) was conducted to investigate 
global gene interactions. Protein expression by immunohistochemistry was conducted 
in 61 tumours. A fourteen DNA repair gene expression panel was associated with poor 
survival in Test and TCGA cohorts. A Cox multivariate model revealed APE1, NBN, 
PMS2, MGMT and PTEN as independently associated with poor prognosis. A DNA repair 
prognostic index incorporating APE1, NBN, PMS2, MGMT and PTEN stratified patients 
in to three prognostic sub-groups with worsening survival. APE1, NBN, PMS2, MGMT 
and PTEN also have predictive significance in patients who received chemotherapy 
and/or radiotherapy. ANN analysis of APE1, NBN, PMS2, MGMT and PTEN revealed 
interactions with genes involved in transcription, hypoxia and metabolic regulation. 
At the protein level, low APE1 and low PTEN remain associated with poor prognosis. 
In conclusion, multiple DNA repair pathways operate to influence biology and clinical 
outcomes in adult high grade gliomas.
INTRODUCTION
Gliomas are the most common primary central 
nervous system tumour in adults [1]. Despite advances 
in surgery, chemotherapy and radiotherapy, patients with 
grade 3 gliomas (anaplastic astrocytomas, anaplastic 
oligodendrogliomas and anaplastic oligoastrocytomas) 
have a five year survival rate of 27% [2]. The outcome for 
grade 4 gliomas (glioblastoma (GBM)) is even worse [3], 
with an estimated 2 year survival rate of about 26.5% [3]. 
Aggressive biology and therapy resistance is a formidable 
clinical problem. Hence biomarker driven stratification of 
patients is a high priority. 
Alkylating chemotherapeutic agents such as 
temozolomide, procarbazine and lomustine, as well as 
radiation therapy, are frequently used in the treatment of 
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high grade gliomas [4, 5]. Although chemotherapy and 
radiotherapy exert cytotoxic effects through genomic 
DNA damage, glioma cancer cells, in common with 
normal cells, have an armoury of DNA repair mechanisms 
to combat such DNA damage. Proficient DNA repair 
may promote cancer cell survival leading to treatment 
resistance and poor clinical outcome. O6-methylguanine 
DNA methyltransferase (MGMT) is a key protein involved 
in the direct repair of O6-methylguanine lesions induced 
by temozolomide chemotherapy. MGMT expression 
status has been extensively studied and has prognostic 
and predictive significance in gliomas [6]. In a study by 
Hegi et al, MGMT promoter methylation was shown to 
be present in just under half of all GBM patients. In this 
same study patients with a methylated MGMT promoter 
who received chemoradiotherapy lived over 6 months 
longer than those that received radiotherapy alone 
[7]. However, despite potential MGMT status directed 
therapy most patients will eventually progress and 
succumb to the disease. This is perhaps not surprising 
as only approximately 9% of all methyl adducts formed 
by temozolomide are O6-methylguanine lesions and the 
rest, including N7-methylguanine (the most common, 
~70%) and N3-methyladenine, are in fact processed 
through the DNA base excision repair (BER) machinery 
in cells [8, 9]. In addition, temozolomide sensitivity may 
also be influenced by proficient DNA mismatch repair 
(MMR) in cells [10]. Single strand breaks, generated as 
DNA repair intermediates during BER or during MGMT 
mediated processing, if unrepaired could eventually lead 
to accumulation of deleterious double strand DNA breaks 
(DSBs) [11]. Homologous recombination pathways are 
required for processing DSBs generated during replication, 
whereas non-homologous end joining (NHEJ) is essential 
for the repair of DSBs generated outside the S-phase of 
the cell cycle [11]. Additional DNA repair pathways, such 
as nucleotide excision repair (NER) [12] and inter-strand 
crosslink repair (ICL repair) [13], are also involved in the 
repair of DNA damaging lesions induced by cytotoxic 
therapy used in gliomas. DNA repair status may not only 
predict resistance to therapy but recent emerging evidence 
also suggests that loss of DNA repair function may lead 
to accelerated accumulation of mutations during cancer 
development that eventually drive a mutator phenotype 
characterised by aggressive biological behaviour and 
adverse outcomes in patients [14]. 
Our hypothesis is that, besides MGMT deregulation, 
multiple other DNA repair pathways may contribute to 
aggressive biology and poor outcomes. In the current 
study, we have comprehensively evaluated the transcript 
levels of 157 genes known to be involved in multiple 
DNA repair pathways in a Test dataset of 191 tumours 
and then validated in ‘The Cancer Genome Atlas’ dataset 
comprising 508 tumours. The data presented here provides 
evidence that multiple DNA repair pathways operate 
together to influence outcomes in high grade gliomas.
RESULTS
DNA repair gene expression and survival in adult 
glioblastomas
 Univariate associations between expression of 157 
DNA repair genes and survival, in the Test set as well 
as in the TCGA dataset was conducted and followed by 
Benjamini and Hochberg False Discovery Rate calculation 
(BH FDR) correction. After applying the BH FDR 
correction 14 probes (for 12 genes) remained significantly 
associated with survival in both datasets (Table 1).
APE1, NBN, PMS2, MGMT and PTEN mRNA 
expression levels independently associated with 
poor prognosis in adult glioblastomas
On multivariate cox regression analysis in the Test 
dataset, APE1 (p=0.000810), Rad23B (p=0.000167), 
PMS2 (p=0.000190), NBN (p=0.000846), MGMT 
(p=0.001326) and PTEN (p=0.001108) were independent 
predictors of survival in GBM. In the TCGA dataset, 
APE1 (p=0.000128), PMS2 (p=0.012998), NBN 
[202905_x_at p=0.000025 and 202907_s_at p=0.003634), 
BRCA2 (p=0.000188), MGMT (p=0.002090) and PTEN 
(p=0.001221) were independently associated with 
survival. As Rad23B (Test dataset), NBN [202907_s_at] 
and BRCA2 (TCGA dataset) were only significant in one 
of the datasets, we excluded these probes and repeated 
the multivariate analyses. The final multivariate models 
including APE1, MGMT, NBN, PMS2 and PTEN in both 
datasets are shown in Table 2. Kaplan Meier survival 
curves for APE1, NBN, PTEN, PMS2 and MGMT in the 
Test and TCGA datasets are shown in Figure 1.
DNA repair prognostic index in adult 
glioblastomas:
We then developed a prognostic index (see methods 
section) incorporating APE1, NBN, PTEN, PMS2 and 
MGMT. As described in the methods section, we initially 
calculated prognostic indices separately for the Test data 
dataset (PI_1) and the TCGA dataset (PI_2). A combined 
prognostic index (PI_3) was then generated using the 
mean β value for each gene from the two datasets. 
PI_3 can be described by the formula:
PI_3 = (APE1*-0.524) + (PMS2*0.498) – 
(NBN*0.620) + (MGMT*0.391) – (PTEN*0.439)
The PI_3 can separate patients with GBM into three 
prognostic sub-groups in both the Test set (Figure 2A) and 
TCGA set (Figure 2C). Patients in prognostic group 1 have 
a significantly better prognosis than patients in prognostic 
group 3 (p1<0.000001, p2<0.000001), where p1 is the p 
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Figure 1: A Kaplan Meier survival curves for overall survival in glioblastoma patients in the Test (A) and TCGA (B) datasets 
stratified by mRNA expression of APE1, NBN, MGMT, PTEN, and PMS2.
Table 1: DNA repair genes associated with poor survival in the Test and the TCGA datasets.
Gene Probe Level associated with worse survival
P value
(Test dataset)
P value
(TCGA dataset)
APE1 210027_s_at Low 0.003 0.000018
PARP2 204752_x_at Low 0.014 0.014
ERCC6 207347_at Low 0.006 0.010
RAD21 200607_s_at Low 0.001 0.004
PTEN 204054_at Low 0.004 0.001
NBN1 202905_x_at Low 0.000001 0.001
MGMT 204880_at High 0.003 0.001
BRCA1 214727_at High 0.009 0.002
PMS2 209805_at High 0.007 0.011
PARP3 209940_at High 0.002 0.004
DDB2 203409_at High 0.000097 0.00005
RAD23B 201222_s_at High 0.000254 0.006
1 Most significant of 3 probes for NBN shown. p values less than or equal to 0.05 are significant.
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value in the Test dataset and p
2
 is the p value in the TCGA 
dataset. 
Using PI_3, curves were constructed to predict 1, 2 
and 3 year survival in GBM patients in both the Test and 
TCGA datasets. Firstly, Kaplan Meier survival life tables 
were analysed to determine the percentage of patients 
alive at 1, 2 and 3 years. The percentage survival at 1 year 
(y axis) was plotted against the median prognostic score 
for patients within each of the 3 prognostic groups (x axis) 
and a 2nd order polynomial curve fitted to the data. This 
process was repeated for 2 and 3 year survival. As shown 
in Figures 2B (Test set) and 2D (TCGA set), the prognostic 
index score can be used to predict survival at 1, 2 and 3 
years for individual patients. For example, patients with a 
prognostic index score of -0.1 have a 15-20% chance of 
surviving to 2 years based on the curves shown in Figures 
2B and 2D. The equations for the predictive curves are 
shown in Supplementary Table S1.
Figure 2: Kaplan Meier survival curves showing separation of patients into 3 prognostic groups by a DNA repair gene 
prognostic score in the Test dataset (A) and the TCGA dataset (C). Survival curves using the DNA repair gene prognostic index 
score to predict 1, 2 and 3 year survival in the Test (B) and TCGA (D) datasets.
Table 2: Multivariate analysis in the Test and TCGA datasets
Gene Test dataset TCGA  dataset
HR (95% CI) P value HR (95% CI) P value
APE1 (210027_s_at) 0.62 (0.45-0.85) 0.002616 0.57 (0.42-0.77) 0.000311
PMS2 (209805_at) 1.84 (1.32-2.55) 0.000299 1.47 (1.17-1.86) 0.000970
NBN (202905_x_at) 0.48 (0.34-0.69) 0.000053 0.60 (0.48-0.77) 0.000045
MGMT (204880_at) 1.55 (1.09-2.19) 0.013562 1.41 (1.11-1.79) 0.004329
PTEN (204054_at) 0.62 (0.45-0.84) 0.001994 0.67 (0.52-0.86) 0.001575
p values less than or equal to 0.05 are significant.
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Predictive significance of APE1, NBN, PMS2, 
MGMT and PTEN mRNA expression in adult high 
grade glioma
We have demonstrated that APE1, NBN, PMS2, 
MGMT and PTEN have prognostic significance. To 
investigate whether these DNA repair genes are predictive 
markers of response to treatment we performed an 
exploratory sub-group analysis in the TCGA dataset. 
Kaplan Meier survival analysis was performed separately 
in patients who had received chemotherapy, and then in 
those had not received chemotherapy, during the course of 
their illness. The same methods were applied to patients 
who had, and had not, received radiotherapy. In patients 
that received chemotherapy during the course of their 
illness low APE1 (p=0.000124), low NBN (p=0.001), 
high PMS2 (p=0.001), high MGMT (p=0.000357) and 
low PTEN (p=0.017) mRNA expression were associated 
with poor survival (Figure 3A). In patients who did 
not receive chemotherapy, only NBN (p=0.005) and 
PTEN (p=0.025) mRNA expression were significantly 
associated with overall survival (Supplementary Figure 
1A). Similarly in patients that received radiotherapy low 
APE1 (p=0.000086), low NBN (p=0.002), high PMS2 
(p=0.002), high MGMT (p=0.000197) and low PTEN 
(p=0.017) mRNA expression were associated with poor 
survival (Figure 3B) while in patients who did not receive 
chemotherapy only NBN (p-=0.048) mRNA expression 
was significantly associated with overall survival 
(Supplementary Figure 1B). 
APE1, PMS2 and PTEN mRNA expression levels 
are associated with age in adult glioblastomas
To investigate whether age may influence abnormal 
DNA repair gene expression, and affect susceptibility to 
the development of gliomas, we assessed the association 
between APE1, NBN, PMS2, MGMT and PTEN mRNA 
expression and age. Low APE1 (p<0.001), low PTEN 
(p<0.001) and high PMS2 (p=0.016) were associated with 
increasing age at diagnosis. No significant associations 
were seen between NBN and MGMT expression and age 
(Supplementary Table 2).
APE1, NBN, PMS2, MGMT and PTEN mRNA 
expression in paediatric high grade gliomas
The data presented in adult tumours provide 
compelling evidence for the role of APE1, NBN, PMS2, 
MGMT and PTEN in gliomagenesis. Moreover, we also 
observed an age related dysregulation of APE1, PMS2 
Figure 3: Kaplan Meier survival curves for overall survival in the TCGA dataset for glioblastoma patients treated with 
chemotherapy (A) and radiotherapy (B) stratified by mRNA expression of APE1, NBN, MGMT, PTEN, and PMS2. 
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and PTEN in adult tumours. To evaluate whether APE1, 
NBN, PMS2, MGMT and PTEN mRNA also have a role in 
paediatric high grade gliomas we proceeded to investigate 
mRNA expression in 53 paediatric high grade gliomas 
and 27 paediatric glioblastomas. Patient demographics 
are shown in supplementary Table 3. As summarized 
in supplementary Table 4, there were no significant 
associations detected between APE1, NBN, PMS2, 
MGMT, PTEN mRNA expression levels and survival in 
both datasets after the Bonferroni correction for multiple 
testing of 16 probesets. Kaplan Meier survival analysis 
with the dichotomized expression levels (low: < median; 
high: > median) also revealed non-significant associations 
between DNA-repair genes and survival in paediatric 
high-grade gliomas (Supplementary Figure 2). Together 
the data implies that APE1, NBN, PMS2, MGMT and 
PTEN do not influence paediatric glioma pathogenesis. 
Artificial neural network analysis in adult 
glioblastomas
The DNA repair association data presented here 
suggest that APE1, NBN, PTEN, PMS2 and MGMT 
together may contribute to aggressive biology and 
influence outcome in patients. An ANNs modelling based, 
data mining approach was used to identify the gene probes 
best able to predict expression of selected DNA repair 
genes (APE1, NBN, PTEN, PMS2 and MGMT). All ANN 
analysis was performed in the TCGA dataset (n=508). 
The algorithm prevented over-fitting of the data by 
incorporating a constrained architecture and a 3 way Monte 
Carlo cross validation. Each of the 22,277 probes were 
utilised singly. The association of each probe with APE1, 
NBN, PTEN, PMS2 and MGMT expression was assessed 
based on the model performance. Probes were ranked 
on their ability to predict APE1, NBN, PTEN, PMS2 or 
MGMT expression based on the root mean squared error of 
the model. This technique has been described previously 
by Lancashire et al [15]. Subsequently, the top 200 probes 
able to predict expression of our DNA repair genes of 
interest were selected and a further ANN based network 
inference algorithm applied [16] which identifies the 
pairwise interactions between these probes. This method 
calculates a magnitude and direction of the interaction of 
each potential pair of probes, a total of 39,800 possible 
interactions ((200 x 200) – 200). 
The 100 interactions having the highest weighting 
were selected and visualised for APE1, PMS2, NBN, 
MGMT and PTEN in a network map (Figure 4). The 
functions of genes involved in each of the five networks 
are shown in Supplementary tables S5 to S9 respectively. 
Key hubs (defined as probes having a large number of 
interactions (≥5) with other probes either targeting the 
node or being targeted by the node) can be seen in all five 
Table 3: Multivariate analysis of APE1, MGMT, NBN, PMS2, PTEN and the top 15 hubs identified from 
artificial neural network analysis.
Gene HR (95% CI) P value
APE1 1.888 (1.361-2.619) 0.000141
MGMT 0.650 (0.503-0.838) 0.001
NBN 1.757 (1.317-2.344) 0.000128
PMS2 0.726 (0.572-0.922) 0.009
PTEN 1.573 (1.206-2.051) 0.001
FOXG1 0.560 (0.449-0.699) <0.000001
TOGLN2 0.715 (0.546-0.937) 0.015
DCLK2 0.726 (0.557-0.945) 0.017
THRA 1.252 (1.006-1.558) 0.044
RFX4 1.445 (1.091-1.913) 0.010
STXBP6 0.739 (0.580-0.942) 0.014
HPRT1 0.752 (0.584-0.968) 0.027
TANC2 0.920 (0.680-1.245) 0.590
CD55 0.841 (0.611-1.157) 0.286
ACACB 0.819 (0.607-1.106) 0.192
ACP5 1.051 (0.800-1.381) 0.720
HIF1AN 1.228 (0.976-1.546) 0.079
ACSL4 1.242 (0.978-1.578) 0.076
PTER 1.247 (0.882-1.762) 0.211
CDH1 0.909 (0.695-1.188) 0.485
Significant p values (≤0.05) are shown in bold.
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A.  APE1 interactome
B.  NBN interactome
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C.  PTEN interactome
D. MGMT interactome
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networks and are represented by large circles. It is likely 
such hubs will have the most influence on the system. The 
three highest ranked hubs within each network, based 
on the strength of their interactions, are shaded yellow. 
The magnitude of the interaction is represented by the 
width of the line, with positive interactions shown as 
red arrows and negative interactions as blue arrows. The 
APE1 interactome shows FOXG1, TGOLN2 and ACACB 
as hubs; the PMS2 interactome shows STXBP6, PTER 
and ACSL4 as hubs; the NBN interactome shows THRA, 
RFX4 and CD55 as hubs; the MGMT interactome shows 
HPRT, DCLK2 and TANC2 as hubs; and lastly the PTEN 
interactome shows CDH1, ACP5 and HIF1AN as hubs. 
The clinical relevance of these hubs was further 
investigated in a Cox multivariate model which also 
included APE1, PMS2, NBN, MGMT and PTEN. The data 
is summarised in Table 3. FOXG1, TOGLN2, DCLK2, 
THRA, RFX4, STXBP6 and HPRT1 remain independently 
associated with poor survival. Of note APE1, PMS2, NBN, 
MGMT and PTEN remained independently significant in 
this analysis.
APE1, NBN, PMS2, MGMT and PTEN protein 
expression in adult high grade gliomas
The data presented above provides evidence that 
APE1, NBN, PMS2, MGMT and PTEN mRNA expression 
levels have prognostic and predictive significance in adult 
tumours. ANN analysis suggests that these genes also 
interact with genes involved in transcription, hypoxia 
and metabolic regulation. To investigate whether the 
prognostic and predictive significance also operates at 
the protein level, we evaluated a cohort of 61 adult high 
grade glioma patients treated at Nottingham University 
Hospitals. As the prognostic significance of low MGMT 
protein expression has been extensive investigated 
previously [7], we focussed on APE1, NBN, PMS2 and 
PTEN protein expression. To evaluate the suitability of 
the antibody used here, we first investigated the protein 
expression of APE1, NBN, PMS2, and PTEN in LN229 
and LN18 human glioma cell lines by Western blot 
analysis. As shown in Figure 5A, robust expression 
of APE1, NBN, PMS2, and PTEN was evident in both 
Figure 4: Artificial neural network analysis in TCGA dataset. Top pair-wise interactions for gene probe markers associated with 
APE1, NBN, PTEN, MGMT and PMS2 expression are shown here. Each gene probe is represented by a node and the interaction weight 
between them as an edge, the width being defined by the magnitude of the weight. Interactions are directed from a source gene to a target 
gene as indicated by arrows. Red interactions indicate an excitatory interaction and blue indicates an inhibitory interaction. Highly linked 
genes represent hubs that are likely to be highly influential or highly regulated in the APE1, NBN, PTEN, MGMT and PMS2 systems. 
Interactome diagrams to show the top 100 interactions of APE1, NBN, PTEN, MGMT and PMS2 are shown here. See results section and 
supplementary Tables S5-S9 for functions of individual genes. 
E. PMS2 interactome
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cell lines. We then proceeded to immunohistochemical 
investigations. Clinicopathological association of APE1, 
NBN, PMS2, and PTEN expression is summarized in 
Supplementary tables S10 to S14 respectively. APE1 
nuclear staining was observed in tumours of all patients 
(Figure 5B2). Median APE1 H-score was 170 (range 
50-250). Low APE1 expression was associated with low 
PTEN expression (p=0.037). On Kaplan Meier survival 
analysis, low APE1 (p=0.031) was significantly associated 
with poor overall survival (Figure 5C1). Nuclear NBN 
expression was observed in tumours of all patients (Figure 
5B3); two tumours also showed cytoplasmic staining. 
Median NBN expression was 70 (range 0-250). There 
were no clinicopathological associations with NBN. 
No significant association (p=0.388) with survival was 
observed in tumours with low or high NBN expression 
(Figure 5C2). For PTEN expression, both nuclear (Figure 
5B4) and cytoplasmic PTEN staining was seen in the 
cohort. Median H-score for nuclear PTEN staining was 10 
(range 0-105) and median H-score for cytoplasmic PTEN 
expression was 50 (range 0-200). Thirteen patients were 
negative for both nuclear and cytoplasmic PTEN staining. 
Low nuclear PTEN expression was associated with grade 4 
gliomas (p=0.006). Similarly, low cytoplasmic expression 
was also associated with grade 4 gliomas (p=0.034). 
On Kaplan Meier survival analysis, low nuclear PTEN 
(p=0.042) expression was significantly associated with 
poor overall survival (Figure 5C3). Cytoplasmic PTEN 
expression was not associated with survival (p=0.545, 
Figure 5C4). Nuclear PMS2 expression was seen in all 
tumours and the median expression H score was 155 
(range 20-250) (Figure 5B5). High PMS2 was associated 
with grade 4 tumours (p=0.010). No significant association 
(p=0.464) with survival was observed in tumours with low 
Figure 5: A Western blots demonstrate expression of APE1 (A1), NBN (A2), PTEN (A3) and PMS2 (A4) in LN229 (1) and 
LN18 (2) glioma cell lines. B Human glioma sections stained using immunohistochemistry technique and the addition of no primary 
antibody (B1), APE1 (B2), NBN (B3), PTEN (B4) and PMS2 (B5). C Kaplan Meier survival curves for overall survival in high grade glioma 
patients in the Nottingham cohort stratified by APE1 (C1), NBN (C2), nuclear PTEN (C3), cytoplasmic PTEN (C4), PMS2 (C5) and APE1/
PTEN combination (C6) protein expression. Also Kaplan Meier survival curves for overall survival in glioblastoma patients in the Test (C7) 
and TCGA (C8) datasets stratified by APE1/PTEN combination mRNA expression.  
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or high PMS2 expression (Figure 5C5). Comparing APE1, 
PTEN, NBN, and PMS2 expression in grade 2, 3 and 4 
tumours only PTEN expression was associated grade, 
with increasing grade being associated with increasing 
levels of PTEN expression (p=0.004). Neither APE1, 
NBN, PMS2, nor PTEN protein expression levels were 
associated with age (Supplementary table 2). We also 
explored whether APE1, NBN, PMS2 and PTEN protein 
expression have predictive significance in this small 
cohort. Although APE1, NBN, PMS2 and PTEN protein 
expression were not associated with survival in patients 
treated with radiotherapy, low PTEN protein expression 
was significantly associated with poor survival (p=0.023) 
in patients treated with chemotherapy (data not shown). 
The data presented above suggest that APE1 
and PTEN protein expression may have prognostic 
significance. Interestingly, a recent preclinical study 
suggested a functional link between APE1 and PTEN 
[17]. APE1 was shown to transcriptionally regulate PTEN 
expression [17]. We therefore analysed APE1 and PTEN 
together in an exploratory study (Figure 5C6). Patients 
with tumours that had low expression of PTEN and APE1 
(n=24) had the worst survival compared tumours that had 
high expression of PTEN and APE1 (n=10) (p=0.027). 
Tumours that were PTEN (low)/APE1 (high) or PTEN 
(high)/APE1 (low) (n=26) had intermediate prognosis 
(Figure 5C6). To validate whether such a relationship 
also exists at the mRNA level we investigated APE1 and 
PTEN together in the Test and the TCGA cohorts. As 
shown in Figures 5C7 and 5C8, patients with tumours that 
had low mRNA expression of PTEN and APE1 had the 
worst survival compared to tumours that had high mRNA 
expression of PTEN and APE1 in Test set (p=0.000238) as 
well as in the TCGA cohort (p=0.000003). Taken together, 
the data provides evidence that APE1 and PTEN have 
prognostic significance in high grade gliomas.
DISCUSSION
This is the first study to comprehensively investigate 
DNA repair in high grade gliomas in the post-genomic era. 
We have shown that besides MGMT, a well-established 
prognostic and predictive biomarker [7], APE1, NBN, 
PMS2 and nuclear PTEN may also independently influence 
survival. Whereas MGMT is involved in direct repair 
[18], APE1 is critical for base excision repair (BER) [19], 
NBN is a component of the MRE11-RAD50-NBN (MRN) 
complex involved in DNA damage signalling [20], PMS2 
is essential for mismatch repair (MMR) [21] and recent 
evidence suggests that nuclear PTEN has an important 
role in DNA double strand break repair and genomic 
stability [22-24]. In the current study, in univariate as well 
as in multivariate analysis, low APE1 mRNA, low NBN 
mRNA and low PTEN mRNA levels were associated with 
poor survival. On the other hand, high MGMT mRNA 
and high PMS2 mRNA expression were associated with 
poor survival. Interestingly in paediatric tumours we did 
not observe any significant associations, implying that 
the pathogenesis in paediatric tumours is unrelated to 
the function of these markers. Taken together, the data 
suggest a complex interaction across multiple DNA repair 
pathways influencing gliomagenesis in adults but not in 
children.
Whereas, the favourable prognostic and predictive 
significance of MGMT silencing through promoter 
hypermethylation has been well established [7], the 
association between high PMS2 mRNA and poor 
prognosis was interesting. Germ-line mutation and loss 
of PMS2 is associated with Turcot’s syndrome (TS), a 
variant of hereditary non-polyposis colorectal cancer 
(HNPCC) syndrome, characterised by colonic polyposis 
and brain tumours. In a review of 100 cases of Turcot’s 
syndrome, TS patients with glioblastoma survived longer 
than patients with sporadic glioblastomas [25, 26]. The 
data presented here, demonstrating that low PMS2 mRNA 
is associated with improved survival in adult glioblastoma 
patients, would concur with the improved survival seen 
in TS patients. However it is important to note that 
PMS2 expression in sporadic paediatric tumours did not 
influence outcome in the current study. Previous studies 
have described a hypermutated phenotype in glioblastoma 
patients with mutations in MMR genes. In one such study, 
6 out of 7 hypermutated tumours had mutations in one 
of the MMR genes MLH1, MSH2, MSH6 and PMS2 
compared to only one tumour in 84 non-hypermutated 
tumours [27]. This may explain why in our study adult 
patients with low PMS2 expression were younger at the 
time of GBM diagnosis. We speculate that PMS2 may 
have essential roles in adult glioma pathogenesis but 
detailed mechanistic studies are required to confirm this 
hypothesis. 
Another unexpected finding in the current study was 
that low APE1 was associated with poor survival. The 
prognostic significance of low APE1 was demonstrated 
at the mRNA and protein level. This is in contrast 
to a previous study by Bobola et. al., where high AP 
endonuclease activity was observed in high grade gliomas 
when compared to low grade gliomas or normal brain 
tissue [28]. Although there was evidence of increased 
APE1 by Western blots in paired samples, the study did 
not investigate APE1 mRNA expression or APE1 protein 
expression by immunohistochemistry or correlate to 
survival. An additional limitation of that study was that 
it included only 39 glioblastomas samples [28]. Although 
high APE1 has been demonstrated in multiple tumour 
types and associated with poor prognosis or response to 
therapy [9, 29], in a recent study in a large cohort of breast 
cancers (n=1285), we observed that APE1 was low in 
about 50% of tumours. Low APE1 expression associated 
with aggressive phenotypes, poor survival and resistance 
to endocrine therapy in patients [30]. Taken together the 
data suggest a complex role for APE1 in human tumours. 
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We speculate that low APE1 in gliomas may promote a 
mutator phenotype where accelerated mutagenesis may 
promote aggressive cancers [40]. Similar to APE1, low 
PTEN mRNA was also associated with poor survival in 
our study and is consistent with previous observations 
in gliomas [31, 32]. At the protein levels, we found that 
nuclear PTEN was associated with adverse prognosis 
but no significant associations were evident for PTEN 
cytoplasmic expression. The data suggests that besides the 
role of PTEN as a negative regulator of the anti-apoptotic 
PI3K/Akt pathway, the recently described nuclear DNA 
repair function of PTEN [22-24] may influence prognosis 
in brain tumours. Interestingly, a preclinical study 
suggested that APE1 may regulate PTEN expression 
through erg-1 transcription factor [17]. APE1 knockdown 
by siRNA in HeLa cells resulted in significant reduction in 
PTEN levels [17]. To investigate whether such functional 
interactions operate in human gliomas we performed 
APE1/PTEN combined mRNA and protein expression 
analysis in our cohorts. A consistent observation at the 
mRNA and the protein level was that tumours with low 
APE1/low PTEN had the worst survival compared to 
tumours with high APE1/high PTEN expression. These 
new observations not only provide prognostic information 
but also suggest that low APE1 or low PTEN glioma cells 
could be targeted for personalized therapy by synthetic 
lethality. For example, we have recently demonstrated 
that APE1 deficient cells are sensitive to ATM kinase 
inhibitors [33] and PTEN deficient cells are sensitive to 
BER inhibitors [34].
In addition to low APE1 and low PTEN, we also 
observed that low NBN mRNA was associated with 
poor survival. Defects in the NBN gene result in a rare 
autosomal recessive disorder known as Nijmegen breakage 
syndrome (NBS) characterised by microcephaly and a 
predisposition to cancers including gliomas. Whether 
adverse prognostic significance of low NBN mRNA seen 
is due to increased genomic instability and the consequent 
aggressive phenotype is not known. Moreover, we did not 
observe any association at the protein level. However, it 
is important to note that, in a previous small study of 26 
glioblastoma patients NBN was overexpressed in tumour 
tissue compared to adjacent normal tissue but was also 
not associated with survival [35]. In contrast, in head 
and neck cancer and in myelodysplastic syndrome high 
NBN appears to be associated with poor survival [36, 
37]. However, a limitation of our immunohistochemistry 
study is that it is small cohort and retrospective. Larger 
prospective investigations are required to confirm these 
observations. Taken together, the data suggests that 
low expression of APE1, NBN and PTEN may increase 
genomic instability, leading to a mutator phenotype [14] 
that could promote accelerated accumulation of mutations 
leading to an aggressive glioma phenotype. 
Previous studies have stratified high grade glioma 
patients in to prognostic groups based on global gene 
expression patterns. For example, Phillips et al identified 
three distinct molecular signatures in high grade glioma: 
Proneural, Proliferative and Mesenchymal. Patients with 
disease classified as ‘Proneural’ had a significantly better 
prognosis than patients with Proliferative or Mesenchymal 
disease. Proneural disease was more commonly seen in 
grade 3 gliomas, and on recurrence disease status was 
found to convert from Proneural to Mesenchymal status. 
Interestingly this study also found that a two gene model, 
incorporating PTEN and delta-like ligand 3 (DLL3), could 
predict survival. In this model patients with low PTEN 
expression had poor survival and those with high PTEN 
expression could be stratified according to DLL3 status 
[38]. Sturm et al describe six distinct methylation clusters 
in GBM patients. In this study isocitrate dehydrogenase 
1 (IDH1) mutation was found to be associated with 
improved survival and with the Proneural classification. 
Patients with the G34 mutation of H3 histone, family 3A 
(H3F3A) had a better prognosis than patients that carried 
the K27 mutation [39]. Taken together the results from 
these, and other studies, suggest that there is significant 
heterogeneity within the high grade glioma population 
and that patients can be stratified in to differing prognostic 
groups based on this data. 
This is the first study to report a DNA repair based 
prognostic index in glioblastomas. The DNA repair 
prognostic index incorporating APE1 mRNA, NBN 
mRNA, PTEN mRNA, PMS2 mRNA and MGMT mRNA 
expression separated patients into three distinct prognostic 
groups with worsening survival in the Test set and was 
further validated in the large TCGA dataset. The data not 
only suggest a DNA repair gene dose dependent biological 
effect in glioma patients but also implies that stratification 
could be employed for personalization of therapy. For 
example, we would suggest that patients in the worst 
prognostic group 3 could be spared aggressive toxic 
therapy that negatively impact quality of life outcomes. 
Alternatively such patients in the prognostic group 3 could 
be offered a personalized trial strategy. We acknowledge 
that the current study is retrospective but our data provides 
a platform for future prospective investigation. Moreover, 
whether such stratification could also be achieved at the 
protein level would require large multicentre studies with 
larger cohort of patients.
In addition to the prognostic significance of our five 
DNA repair genes of interest, our exploratory analysis 
stratifying patients by treatment group suggests that they 
may also have a potential role as predictive markers. 
Due to limitations of the data available we were only 
able to classify patients as to whether they have received 
chemotherapy or radiotherapy during the course of their 
treatment. Our data at the mRNA level demonstrates that 
APE1, MGMT, PTEN and PMS2 were only associated 
with survival in patients that received radiotherapy during 
the course of their treatment. Similarly APE1, MGMT, 
and PMS2 mRNA expression levels were only associated 
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with survival in the chemotherapy treated group. While 
these results are interesting caution should be exerted in 
their interpretation given that the non-treatment subgroups 
are small. It is also difficult to draw conclusions from 
the subgroup analysis in the Nottingham Cohort as the 
numbers are small. For example, while 52 patients were 
known to have received radiotherapy in the Nottingham 
Cohort only two patients were recorded as not receiving 
radiotherapy.
An additional novel feature of our study is that 
we have conducted the first artificial neural network 
based interaction modelling of DNA repair genes in the 
TCGA cohort. The aim of this was to identify genes 
that interacted with the key DNA repair genes identified 
earlier and to identify the most influential genes 
(hubs) in the DNA repair system. The advantage of the 
ANN approach was that it modelled using non-linear 
functions and was not constrained by reliance on linear 
mathematics [40]. We focussed this interactomic study 
on APE1 mRNA, NBN mRNA, PTEN mRNA, PMS2 
mRNA and MGMT mRNA interactions. Several key 
hubs with potential roles in glioma pathogenesis were 
identified. As additional validation we incorporated these 
hubs in a multivariate model which also included APE1, 
NBN, PTEN, PMS2 and MGMT. We found that FOXG1, 
THRA, RFX4, STXBP6, HPRT1, DCLK2 and TOGLN2 
were independently prognostic along with APE1, NBN, 
PTEN, PMS2 and MGMT. Reassuringly, FOXG1, THRA, 
STXBP6 and RFX4 genes have previously been reported 
to be involved in glioma pathogenesis [41-43]. In fact 
FOXG1 (Forkhead box protein G1), the most significantly 
associated independent variable in the current study, 
is a key transcriptional repressor protein with essential 
roles in brain development. Germ-line mutation in the 
FOXG1 gene has been associated with atypical Rett 
syndrome characterised by microcephaly and psychomotor 
symptoms [41]. More importantly, a recent study has 
provided compelling pre-clinical evidence for the role 
of FOXG1 in glioblastoma growth. FOXG1 knockdown 
resulted in impaired glioblastoma growth in vitro and in 
vivo in that study [44]. Interestingly, the thyroid hormone 
receptor (THRA) axis has also been shown to be essential 
for glioblastoma growth [42]. RFX4 (regulatory factor X 
4), a transcription factor known to influence HLA Class 
II expression is overexpressed in gliomas compared to 
normal brain tissues [43]. In another study, STXBP6 
(syntaxin binding protein 6-amisyn) that is known to 
be involved in vesicle-mediated intracellular transport 
was found to be differentially expressed in high versus 
low grade gliomas [45]. Taken together the data not only 
validates the ANN approach utilized in the current study 
but also suggests a complex interaction between DNA 
repair, transcription and other essential cellular processes 
in glioma pathogenesis. 
Given the essential role of APE1, NBN, PTEN, 
PMS2 and MGMT in adult tumours we explored if 
these genes also influence outcomes in paediatric high 
grade gliomas/glioblastomas. Previous studies have 
demonstrated that, at the molecular level, paediatric 
high grade glioma differ from adult tumours [46]. For 
example, PTEN mutations are relatively common in adult 
high grade glioma but are less common in childhood 
tumours [47]. MGMT expression also varies between 
adult and paediatric gliomas; whereas more than 85% 
of paediatric patients demonstrate normal or low MGMT 
levels [48], in adult tumours only 50% show low MGMT 
expression [7]. These molecular differences imply that the 
pathogenesis of childhood tumours differs from that seen 
in adult glioma and may explain why the results from our 
paediatric cohort vary from that seen in our adult cohort. 
However, in common with their adult counterparts, earlier 
studies have shown that the small numbers of children 
with PTEN mutated tumours have a poor prognosis 
[48]. In addition, childhood tumours with a methylated 
MGMT promoter have previously been shown to have 
a higher average survival than those without promoter 
methylation [48]. As our paediatric cohort is small, and 
PTEN mutation and variation in MGMT expression is 
relatively uncommon, it is conceivable that we were not 
able to detect any association with survival due to sample 
size. Interestingly in our cohort there is a trend towards 
low PTEN expression being associated with poor survival, 
although this does not retain significance after correction 
for multiple comparisons. Larger scale studies are required 
to clarify the role of DNA repair in paediatric high grade 
glioma. 
In conclusion, our study suggests that multiple 
DNA repair pathways may operate to influence biology 
and clinical outcomes in high grade adult gliomas. APE1, 
NBN, PTEN, PMS2 and MGMT combined prognostication 
could allow stratification and personalization of therapy. 
MATERIALS AND METHODS
Adult Glioblastoma gene expression data sets
Test set
The Test set (E-GEOD-13041) was obtained from 
http://www.ebi.ac.uk/arrayexpress/ and is a publically 
available gene expression dataset for patients with a 
diagnosis of GBM. This dataset contained microarray 
gene profiling data for 267 patients using 3 different 
Affymetrix platforms. 191 GBM patients were included 
in the subsequent data analysis for the Test dataset, all of 
whom were profiled using the Affymetrix U133A array. 
The median age of patients in the Test dataset was 54 
years (range 18-86 years). 73/191 (38.2%) of patients 
were female. Patients were followed up for a median of 
385 days (range 7-3353 days) and at the end of follow-up 
176/191 (92.1%) had died.
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Validation set
The Validation dataset was downloaded from ‘The 
Cancer Genome Atlas (TCGA)’ (http://cancergenome.
nih.gov/) for patients with a diagnosis of GBM with 
gene expression data assessed using the HT_HG_U133A 
Affymetrix array. 548 files were identified in this dataset. 
Duplicate cases were removed alongside cases with 
missing survival data or identified as not meeting the 
original study criteria. A total of 508 cases were included 
in the subsequent analyses. In the TCGA dataset the 
median age of patients was 59 years (range 10-89 years). 
200/508 (39.4%) of patients were female. Karnofsky 
performance status (KPS) data was available for 381 
patients; median KPS was 80 (range 20-100). 416/508 
(81.9%) of patients had died after a median follow up time 
of 353 days (range 2-3880 days). 351 (69.1%) were treated 
with chemotherapy; 294 (57.9%) received temozolomide. 
Baseline demographic data for the TCGA dataset is shown 
in Supplementary Table S15.
Bioinformatics
DNA repair gene association studies
We investigated the clinical significance of 188 
DNA repair genes (Supplementary Table S16) in the 
Test and TCGA datasets. A total of 157 DNA repair 
genes, represented by 248 probes, were present in both 
datasets and included in subsequent analyses. Baseline 
demographic data was also extracted including: age, 
gender, performance status, and treatment and survival 
data (if available). Xtile (version 3.6.1, Yale University, 
USA) was used to dichotomise (high/low) levels of 
DNA gene expression prior to Kaplan Meier survival 
analysis. Kaplan Meier survival curves were constructed 
in SPSS (Version 20, Chicago, USA) for 248 probes (in 
both the Test and TCGA datasets) and a log rank score 
calculated. The Benjamini and Hochberg False Discovery 
Rate calculation (BH FDR) [49] was applied to account 
for multiple comparisons. Cox multivariate regression 
models were constructed for each dataset including probes 
significant (with BH FDR correction) in both datasets 
(n=14). Non-significant probes after the first round of 
analysis were removed and the analysis re-run. This was 
repeated until only significant probes remained (6 probes 
in the Test dataset and 7 probes in the TCGA dataset). 
The models for the two datasets were compared and the 
analysis re-run with the five probes significant in both 
datasets.
DNA repair prognostic index
Prognostic indices were calculated for each 
dataset (PI_1=prognostic index for the Test dataset and 
PI_2=prognostic index for the TCGA dataset) using the 
following equation:
Σ (DNA repair gene expression level* β value)
where DNA repair gene expression is represented 
as 0 (low) or 1 (high) and the β value is obtained from 
the final multivariate model described above. A combined 
prognostic index (PI_3) was also calculated using the 
mean β value for each gene from the two datasets. The 
prognostic index calculated from each dataset (PI_1 and 
PI_2) as well as the combined prognostic index (PI_3), 
was then tested in both the Test and TCGA datasets. 
Patients were divided into 3-4 prognostic groups based 
on their prognostic score and Kaplan Meier survival 
curves were constructed. The log rank test was applied 
to assess the survival difference between groups. The 
combined prognostic index (PI_3) separated patients into 
3 statistically significant prognostic groups in the Test and 
TCGA datasets. 
Using PI_3, curves were constructed to predict 1, 2 
and 3 year survival in GBM patients in both the Test and 
TCGA datasets. Firstly, Kaplan Meier survival life tables 
were analysed to determine the percentage of patients 
alive at 1, 2 and 3 years. The percentage survival at 1 year 
(y axis) was plotted against the median prognostic score 
for patients within each of the 3 prognostic groups (x axis) 
and a 2nd order polynomial curve fitted to the data. This 
process was repeated for 2 and 3 year survival. 
Artificial neural network (ANN) analysis
 Artificial neural network (ANN) analysis was used 
to identify genes that interact with PTEN, APE1, NBN, 
MGMT and PMS2 in the TCGA dataset. The probes 
selected to represent each gene were those used in the 
prognostic index (PTEN 204054_at, APE1 210027_s_at, 
NBN 202905_x_at, MGMT 204880_at and PMS2 209805_
at). A total of 22,277 probes were screened to identify 
those best able to predict PTEN, APE1, NBN, MGMT or 
PMS2 expression. The technique used was a non-linear, 
ANN modelling based, data mining approach which 
employed supervised learning with a multilayer perception 
architecture modified with a sigmoidal transfer function. 
The model weights were updated after each epoch by a 
feed forward back propagation algorithm. A Monte-Carlo 
cross validation strategy was employed prior to ANN 
training, where the samples were randomly segregated 
in to three subsets; 60% for training, 20% for testing 
and 20% for validation of model performance for 50 
bootstraps [15]. The network momentum and learning rate 
were respectively set as 0.1 and 0.5. Two hidden nodes 
were utilised. The output node was coded as 0 if a case 
was low PTEN, APE1, NBN, MGMT or PMS2 expression 
(<median) and 1 if high PTEN, APE1, NBN, MGMT 
or PMS2 expression (>median). Inputs were ranked in 
ascending order based on their classification error. The top 
200 predictive genes identified were then applied to an 
ANN based network inference algorithm as described in 
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earlier studies [16]. This model predicted a weighted link 
(direction and magnitude) between each of the top 100 
gene probe markers associated with PTEN, APE1, NBN, 
MGMT or PMS2 expression. The 100 strongest pairwise 
interactions were then visualised as a map with Cytoscape 
(Version 3.0.1, Cytoscape Consortium, San Diego, USA) 
[50]. 
In a second bioinformatics analysis, we sought to 
obtain a robust ranking of genes that are differentially 
expressed between the mRNA APE1+, NBN+, PTEN+, 
MGMT+ or PMS2 + cases and the mRNA APE1-, NBN-
, PTEN-, MGMT- or PMS2- and have high predictive 
power, by applying an ensemble sample classification 
method within a leave-one-out cross-validation scheme. 
For this purpose, the 508 patient samples were first 
grouped into 508 different training/test set partitions, 
using 507 samples for the training sets and the remaining 
sample as the test set. For each of the 507 training sets 
differentially expressed genes were selected independently 
with the “Empirical Bayes moderated t-statistic” [51] 
and used to train a machine learning model, which was 
evaluated based on the left-out sample (a procedure 
known as “external cross-validation”). To classify the 
left-out sample, the prediction results of four algorithms 
(Support Vector Machine, Random Forest, kNN and 
Prediction Analysis for Microarrays, with all parameters 
being optimised by using a grid search within a nested 
cross-validation) [52] were combined to a majority-vote 
ensemble classifier as to compensate for the inevitable 
inherent biases and variances that exists amongst each of 
these machine learning algorithms. In order to rank the 
genes based on the cross-validation results, their frequency 
of occurrence in the list of significantly differentially 
expressed genes (p value < 0.05) across different cross-
validation cycles was recorded, and genes received higher 
scores the more often they had been selected. All steps 
of the analysis were conducted using an in-house web-
application for microarray analysis, available at www.
arraymining.net.
Supplementary Figure 3 summarises the methods 
used to develop the prognostic index and for ANN 
analysis.
Evaluation of APE1, NBN, PTEN and PMS2 
protein expression 
Investigation of the protein expression of APE1, 
NBN, PTEN and PMS2 in high grade glioma was carried 
out on paraffin-embedded tumour sections from 61 high 
grade glioma patients treated at Nottingham University 
Hospitals (NUH) between 2005 and 2011. Forty-three 
(70.5%) high grade patients were male and 19 patients 
(31.1%) were alive at the end of the study. Eighteen 
patients (29.5%) had been diagnosed with a glioma prior 
to inclusion in the study; 4 (6.6%) had already received 
radiotherapy and 3 (4.9%) had previously received 
chemotherapy. Median age at trial histology was 54 
years (range 22-81 years). In total 52 (85.2%) patients 
were known to have received radiotherapy during the 
course of their illness and 39 (63.9%) were known 
to have received chemotherapy. The median number 
of lines of chemotherapy given was one (range 0-4). 
Baseline demographic information for the Nottingham 
Cohort is shown in Supplementary Table S17. The 
immunohistochemistry study has been approved by 
the Regional Ethics Committee (Reference number 08/
H0406/102). An additional 18 patients with low grade 
(grade 2) glioma were also stained for APE1, NBN, PTEN 
and PMS2.
Immunohistochemical staining was performed 
using the Leica Novolink max polymer detection system 
and Thermo Scientific Shandon Sequenza chambers as 
per the manufacturer’s instructions. Slides were heated to 
60°C prior to passage through xylene to deparaffinise and 
then rehydration in decreasing concentrations of alcohol. 
Citrate buffer (pH 6) heated to 95°C (20 minutes) was 
used for antigen retrieval. All sections were incubated with 
primary antibody (APE1 1:300 [Novus Biologicals], NBN 
1:150 [Sigma], PTEN 1:150 [Cell Signalling, clone D4.3] 
and PMS2 1:200 [BD Pharmingen, clone A16-4]) for 1 
hour at room temperature. 3,3’ – Diaminobenzidine (DAB) 
was used as a chromogen. All sections were counterstained 
with haematoxylin. Slides were dehydrated in increasing 
concentrations of alcohol and passed through xylene 
prior to mounting. A negative control was performed by 
omission of the primary antibody and control sections 
were included in each run.
Tumour sections were evaluated by a 
Histopathologist (TA) blinded to the clinicopathological 
characteristics of the individual. A representative section 
of the slide was scored and the intensity of nuclear or 
cytoplasmic staining grouped as follows: 0 = no staining, 
1 = weak staining, 2 = moderate staining and 3 = strong 
staining. The percentage of each staining category was 
estimated, the values summed and an H score calculated 
(range 0-300). Two patients had more than one pathology 
specimen from the same procedure and therefore an 
average H score was calculated. 
Statistical analysis of immunohistochemistry data
Baseline demographic data were collected, in 
addition to treatment and survival information. Data 
analysis was performed in SPSS (Version 20, Chicago, 
USA). Categorical variables are expressed as number 
and percentage and continuous variables as median and 
range. Xtile (Version 3.6.1, Yale University, USA) was 
used to dichotomise H-score expression of APE1 (low 
≤160, high >160), NBN (low ≤85, high >85), nuclear 
PTEN (low ≤50, high >50), cytoplasmic PTEN (low ≤10, 
high >10) and PMS2 (low ≤120, high >120) into high 
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and low expression. Kaplan Meier survival curves were 
constructed for each marker and the log rank test used to 
determine the survival difference between groups. Chi 
squared tests (with or without Yates’ continuity correction, 
as appropriate) were used to assess the association 
between two categorical variables. Mann Whitney U test 
was used to compare continuous, non-normally distributed 
variables between two groups. Cox multivariate analysis 
was performed to determine independent predictors of 
survival. Statistical significance was defined as p≤0.05.
Cells lines, tissue culture and Western blot 
analysis
LN229 and LN18 human glioma cell lines were 
purchased from ATCC and were grown in Dulbecco’s 
Modified Eagle Medium (DMEM with 4500mg/L glucose, 
L-glutamine, sodium pyruvate) with the addition of 5% 
foetal bovine serum. 5ml of 1% penicillin/streptomycin 
(10,000 units penicillin and 10mg streptomycin/mL) 
was added to the media. All media and additives were 
purchased from Sigma, UK. To evaluate the specificity 
of the antibodies used for the immunohistochemical 
study cell lysates were prepared and Western blot 
analysis performed. Primary antibodies were incubated 
at room temperature for 1 hour (APE1 1:1000 dilution, 
NBN 1:500 dilution, PTEN 1:500 dilution, PMS2 1:500 
dilution and beta actin 1:10000 dilution [Abcam] or beta 
tubulin 1:2000 [Abcam]). Infrared dye-labelled secondary 
antibodies (Li-Cor) [IRDye 800CW Donkey Anti-Rabbit 
IgG and IRDye 680CW Donkey Anti-Mouse IgG] were 
incubated at a dilution of 1:10000 for 1 hour. Membranes 
were scanned with a Li-Cor Odyssey machine (700 and 
800nm) to determine protein expression.
Paediatric high-grade glioma and glioblastoma 
gene expression data analysis
Two independent microarray gene expression 
data sets of paediatric high-grade glioma (pHGG) and 
paediatric glioblastoma (pGBM) were used in this 
analysis. The pHGG dataset (GSE19578) contained mRNA 
expression profiles from 53 pHGG patients with median 
age of 9.9 years (range from 0 to 23 years) and the median 
follow-up of 1.2 years (range from 0.1 to 7.6 years). 
The pGBM dataset (GSE34824) contained expression 
profiles from tumour samples of 27 pGBM patients with 
the median age of 11.5 years (range from 2 to 20 years). 
16/27 (59.3%) of pGBM patients were male. The median 
overall survival of these 27 pGBM patients was 12 months 
(range from 5 to 55 months). In both datasets, Affymetrix 
HG-U133 Plus arrays were used for the mRNA profiling. 
The raw data was downloaded from the GEO database 
and pre-processed with robust multi-array average (RMA) 
algorithm. Probesets that are ‘absent’ (present / absent 
call using MAS5) in all samples were removed from the 
analysis and the remaining probesets were mapped to 
Entrez GeneID using Bioconductor annotation package. 
Normalized expression values for 16 probesets (mapped to 
5 DNA repair genes) were extracted and tested for survival 
using the univariate Cox proportional hazards regression 
model. The most significant probeset from the regression 
model for APE1, MGMT, NBN, PMS2 and PTEN was 
selected and the Kaplan Meier survival analysis was 
performed with expression levels dichotomised in to low/
high expression at the median.
ACKNOWLEDGEMENTS
CP is in receipt of a Medical Research Council 
Clinical Research Training Fellowship (MR/J008001/1).
Conflict of interest:
The authors declare that they have no conflict of 
interest.
REFERENCES
1. Cancer Research UK (2013) Brain, other CNS and 
intracranial tumours incidence statistics. Available via 
www.cancerresearchuk.org/cancer-info/cancerstats/types/
brain/incidence. Accessed 14 April 2013.
2. Cancer Research UK (2012) Statistics and outlook for brain 
tumours. Available via www.cancerresearchuk.org/cancer-
help/type/brain-tumour/treatment/statistics-and-outlook-for-
brain-tumours. Accessed 17 April 2013. 
3. Schwartzbaum, JA, Fisher JL, Aldape KD and Wrensch M. 
Epidemiology and molecular pathology of glioma. Nature 
clinical practice Neurology. 2006; 2(9):494-503; quiz 491 
p following 516.
4. Stupp, R, Tonn JC, Brada M and Pentheroudakis G. 
High-grade malignant glioma: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up. Annals 
of oncology : official journal of the European Society for 
Medical Oncology / ESMO. 2010; 21 Suppl 5:v190-193.
5. Stupp, R, Mason WP, van den Bent MJ, Weller M, Fisher 
B, Taphoorn MJB, Belanger K, Brandes AA, Marosi 
C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, 
Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy 
plus Concomitant and Adjuvant Temozolomide for 
Glioblastoma. New England Journal of Medicine. 2005; 
352(10):987-996.
6. Weller, M, Stupp R, Reifenberger G, Brandes AA, van 
den Bent MJ, Wick W and Hegi ME. MGMT promoter 
methylation in malignant gliomas: ready for personalized 
medicine? Nature reviews Neurology. 2010; 6(1):39-51.
7. Hegi, ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet 
N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani 
Oncotarget5780www.impactjournals.com/oncotarget
L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, 
Janzer RC and Stupp R. MGMT gene silencing and benefit 
from temozolomide in glioblastoma. The New England 
journal of medicine. 2005; 352(10):997-1003.
8. Dianov, GL and Hubscher U. Mammalian base excision 
repair: the forgotten archangel. Nucleic Acids Res. 2013; 
41(6):3483-3490.
9. Kim, YJ and Wilson DM, 3rd. Overview of base excision 
repair biochemistry. Curr Mol Pharmacol. 2012; 5(1):3-13.
10. Johannessen, TC and Bjerkvig R. Molecular mechanisms 
of temozolomide resistance in glioblastoma multiforme. 
Expert Rev Anticancer Ther. 2012; 12(5):635-642.
11. Chapman, JR, Taylor MR and Boulton SJ. Playing the end 
game: DNA double-strand break repair pathway choice. 
Mol Cell. 2012; 47(4):497-510.
12. Kamileri, I, Karakasilioti I and Garinis GA. Nucleotide 
excision repair: new tricks with old bricks. Trends Genet. 
2012; 28(11):566-573.
13. Deans, AJ and West SC. DNA interstrand crosslink repair 
and cancer. Nat Rev Cancer. 2011; 11(7):467-480.
14. Bielas, JH, Loeb KR, Rubin BP, True LD and Loeb LA. 
Human cancers express a mutator phenotype. Proc Natl 
Acad Sci U S A. 2006; 103(48):18238-18242.
15. Lancashire, LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre 
C, Weigelt B, Abdel-Fatah TM, Green AR, Mukta R, 
Blamey R, Paish EC, Rees RC, Ellis IO and Ball GR. A 
validated gene expression profile for detecting clinical 
outcome in breast cancer using artificial neural networks. 
Breast Cancer Res Treat. 2010; 120(1):83-93.
16. Lemetre, C. Artificial neural network based algorithm for 
biomolecular interaction modeling. Bio-inspired systems: 
computational and ambient intellegence. Lecture Notes in 
Computer Science. 2009; 5517:877-885.
17. Fantini, D, Vascotto C, Deganuto M, Bivi N, Gustincich S, 
Marcon G, Quadrifoglio F, Damante G, Bhakat KK, Mitra 
S and Tell G. APE1/Ref-1 regulates PTEN expression 
mediated by Egr-1. Free Radic Res. 2008; 42(1):20-29.
18. Gerson, SL. MGMT: its role in cancer aetiology and cancer 
therapeutics. Nat Rev Cancer. 2004; 4(4):296-307.
19. Tell, G, Quadrifoglio F, Tiribelli C and Kelley MR. The 
many functions of APE1/Ref-1: not only a DNA repair 
enzyme. Antioxid Redox Signal. 2009; 11(3):601-620.
20. Kobayashi, J, Antoccia A, Tauchi H, Matsuura S and 
Komatsu K. NBS1 and its functional role in the DNA 
damage response. DNA Repair (Amst). 2004; 3(8-9):855-
861.
21. Pena-Diaz, J and Jiricny J. Mammalian mismatch repair: 
error-free or error-prone? Trends Biochem Sci. 2012; 
37(5):206-214.
22. Bassi, C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller 
SJ, Mak TW, Neel BG, Raught B and Stambolic V. Nuclear 
PTEN controls DNA repair and sensitivity to genotoxic 
stress. Science. 2013; 341(6144):395-399.
23. Ming, M and He YY. PTEN in DNA damage repair. Cancer 
Lett. 2012; 319(2):125-129.
24. Meyn, RE. Linking PTEN with genomic instability and 
DNA repair. Cell Cycle. 2009; 8(15):2322-2323.
25. Qualman, SJ, Bowen J and Erdman SH. Molecular basis of 
the brain tumor-polyposis (Turcot) syndrome. Pediatr Dev 
Pathol. 2003; 6(6):574-576.
26. Paraf, F, Jothy S and Van Meir EG. Brain tumor-polyposis 
syndrome: two genetic diseases? J Clin Oncol. 1997; 
15(7):2744-2758.
27. Comprehensive genomic characterization defines human 
glioblastoma genes and core pathways. Nature. 2008; 
455(7216):1061-1068.
28. Bobola, MS, Blank A, Berger MS, Stevens BA and Silber 
JR. Apurinic/Apyrimidinic endonuclease activity is 
elevated in human adult gliomas. Clin Cancer Res. 2001; 
7(11):3510-3518.
29. Abbotts, R and Madhusudan S. Human AP endonuclease 
1 (APE1): from mechanistic insights to druggable target in 
cancer. Cancer Treat Rev. 2010; 36(5):425-435.
30. Abdel-Fatah, TM, Perry C, Moseley P, Johnson K, Arora 
A, Chan S, Ellis IO and Madhusudan S. Clinicopathological 
significance of human apurinic/apyrimidinic endonuclease 
1 (APE1) expression in oestrogen-receptor-positive breast 
cancer. Breast Cancer Res Treat. 2014; 143(3):411-421.
31. Sano, T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, 
Hess KR, Myers JN, Hong YK, Yung WK and Steck PA. 
Differential expression of MMAC/PTEN in glioblastoma 
multiforme: relationship to localization and prognosis. 
Cancer Res. 1999; 59(8):1820-1824.
32. Ermoian, RP, Furniss CS, Lamborn KR, Basila D, Berger 
MS, Gottschalk AR, Nicholas MK, Stokoe D and Haas-
Kogan DA. Dysregulation of PTEN and protein kinase B is 
associated with glioma histology and patient survival. Clin 
Cancer Res. 2002; 8(5):1100-1106.
33. Sultana, R, McNeill DR, Abbotts R, Mohammed MZ, 
Zdzienicka MZ, Qutob H, Seedhouse C, Laughton CA, 
Fischer PM, Patel PM, Wilson DM, 3rd and Madhusudan 
S. Synthetic lethal targeting of DNA double-strand break 
repair deficient cells by human apurinic/apyrimidinic 
endonuclease inhibitors. Int J Cancer. 2012.
34. Abbotts, R, Thompson N and Madhusudan S. DNA repair 
in cancer: emerging targets for personalized therapy. Cancer 
management and research. 2014; 6:77-92.
35. Seol, HJ, Yoo HY, Jin J, Joo KM, Kong DS, Yoon SJ, 
Yang H, Kang W, Lim DH, Park K, Kim JH, Lee JI and 
Nam DH. Prognostic implications of the DNA damage 
response pathway in glioblastoma. Oncology reports. 2011; 
26(2):423-430.
36. Yang, MH, Chiang WC, Chou TY, Chang SY, Chen 
PM, Teng SC and Wu KJ. Increased NBS1 expression 
is a marker of aggressive head and neck cancer and 
overexpression of NBS1 contributes to transformation. Clin 
Cancer Res. 2006; 12(2):507-515.
37. Kefala, M, Papageorgiou SG, Kontos CK, Economopoulou 
Oncotarget5781www.impactjournals.com/oncotarget
P, Tsanas A, Pappa V, Panayiotides IG, Gorgoulis VG, 
Patsouris E and Foukas PG. Increased expression of 
phosphorylated NBS1, a key molecule of the DNA damage 
response machinery, is an adverse prognostic factor 
in patients with de novo myelodysplastic syndromes. 
Leukemia research. 2013; 37(11):1576-1582.
38. Phillips, HS, Kharbanda S, Chen R, Forrest WF, Soriano 
RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu 
L, Williams PM, Modrusan Z, Feuerstein BG and Aldape 
K. Molecular subclasses of high-grade glioma predict 
prognosis, delineate a pattern of disease progression, 
and resemble stages in neurogenesis. Cancer cell. 2006; 
9(3):157-173.
39. Sturm, D, Witt H, Hovestadt V, Khuong-Quang DA, Jones 
DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, 
Kool M, Zapatka M, Becker N, Zucknick M, Hielscher 
T, Liu XY, et al. Hotspot mutations in H3F3A and IDH1 
define distinct epigenetic and biological subgroups of 
glioblastoma. Cancer cell. 2012; 22(4):425-437.
40. Powe, DG, Dhondalay GK, Lemetre C, Allen T, Habashy 
HO, Ellis IO, Rees R and Ball GR. DACH1: its role as a 
classifier of long term good prognosis in luminal breast 
cancer. PloS one. 2014; 9(1):e84428.
41. Florian, C, Bahi-Buisson N and Bienvenu T. FOXG1-
Related Disorders: From Clinical Description to Molecular 
Genetics. Mol Syndromol. 2012; 2(3-5):153-163.
42. Davis, FB, Tang HY, Shih A, Keating T, Lansing L, 
Hercbergs A, Fenstermaker RA, Mousa A, Mousa SA, 
Davis PJ and Lin HY. Acting via a cell surface receptor, 
thyroid hormone is a growth factor for glioma cells. Cancer 
Res. 2006; 66(14):7270-7275.
43. Matsushita, H, Uenaka A, Ono T, Hasegawa K, Sato S, 
Koizumi F, Nakagawa K, Toda M, Shingo T, Ichikawa 
T, Noguchi Y, Tamiya T, Furuta T, Kawase T, Date I and 
Nakayama E. Identification of glioma-specific RFX4-E 
and -F isoforms and humoral immune response in patients. 
Cancer Sci. 2005; 96(11):801-809.
44. Verginelli, F, Perin A, Dali R, Fung KH, Lo R, Longatti 
P, Guiot MC, Del Maestro RF, Rossi S, di Porzio U, 
Stechishin O, Weiss S and Stifani S. Transcription factors 
FOXG1 and Groucho/TLE promote glioblastoma growth. 
Nat Commun. 2013; 4:2956.
45. Vital, AL, Tabernero MD, Castrillo A, Rebelo O, Tao H, 
Gomes F, Nieto AB, Resende Oliveira C, Lopes MC and 
Orfao A. Gene expression profiles of human glioblastomas 
are associated with both tumor cytogenetics and 
histopathology. Neuro-oncology. 2010; 12(9):991-1003.
46. MacDonald, TJ, Aguilera D and Kramm CM. Treatment 
of high-grade glioma in children and adolescents. Neuro-
oncology. 2011; 13(10):1049-1058.
47. Pollack, IF, Hamilton RL, James CD, Finkelstein SD, 
Burnham J, Yates AJ, Holmes EJ, Zhou T and Finlay 
JL. Rarity of PTEN deletions and EGFR amplification in 
malignant gliomas of childhood: results from the Children’s 
Cancer Group 945 cohort. Journal of neurosurgery. 2006; 
105(5 Suppl):418-424.
48. Pollack, IF, Hamilton RL, Sobol RW, Burnham J, Yates 
AJ, Holmes EJ, Zhou T and Finlay JL. O6-methylguanine-
DNA methyltransferase expression strongly correlates with 
outcome in childhood malignant gliomas: results from the 
CCG-945 Cohort. J Clin Oncol. 2006; 24(21):3431-3437.
49. Benjamini, Y, Hochberg, Y. Controlling the False 
Discovery Rate: A Practical and Powerful Approach to 
Multiple Testing. Journal of the Royal Statistical Society 
Series B (Methodological). 1995; 57(1):289-300.
50. Smoot, ME, Ono K, Ruscheinski J, Wang PL and Ideker 
T. Cytoscape 2.8: new features for data integration and 
network visualization. Bioinformatics. 2011; 27(3):431-
432.
51. Smyth, GK. Linear models and empirical bayes methods for 
assessing differential expression in microarray experiments. 
Statistical applications in genetics and molecular biology. 
2004; 3:Article3.
52. Tibshirani, R, Hastie T, Narasimhan B and Chu G. 
Diagnosis of multiple cancer types by shrunken centroids 
of gene expression. Proc Natl Acad Sci U S A. 2002; 
99(10):6567-6572.
